基于代谢组学的药源性肝损伤生物标志物发现

Metabolite biomarkers of drug-induced liver injury

药源性肝损伤(DILI)是临床常见的药物不良反应之一,也是导致新药研发终止、限用或撤市的一个主要原因.目前,DILI的早期诊断和发病机制阐明都存在很大困难,其中一个重要原因就是缺少灵敏、准确的生物标志物.代谢组学重点研究处于生物信息流末端的内源性小分子代谢物,为疾病相关生物标志物的发现提供新的思路.本研究探讨了近期基于代谢组学的DILI生物标志物的相关代谢物.

Drug-induced liver injury（ DILI） is one of the most common adverse drug reactions in clinic,and is the main cause of discontinuation,restriction or withdrawal of new drug research and development. At present,DILI early diagnosis and study of its pathogenesis are in great difficulties for the lack of sensitive and accurate biomarkers. Metabolomics focuses on the endogenous small molecule metabolites at the end of the biological information flow,providing a new idea for the discovery of diseaserelated biomarkers. This paper provides an overview of research progresses on the metabolite biomarkers of DILI.